

University of Groningen

Fatty liver disease

Edens, Mireille Angélique

IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.

Document Version

Publisher's PDF, also known as Version of record

Publication date:

2011

[Link to publication in University of Groningen/UMCG research database](#)

Citation for published version (APA):

Edens, M. A. (2011). *Fatty liver disease: pathophysiology & assessment*. s.n.

Copyright

Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

The publication may also be distributed here under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license. More information can be found on the University of Groningen website: <https://www.rug.nl/library/open-access/self-archiving-pure/taverne-amendment>.

Take-down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Downloaded from the University of Groningen/UMCG research database (Pure): <http://www.rug.nl/research/portal>. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.

Abbreviations

LIST OF ABBREVIATIONS

A

AFLD, alcoholic fatty liver disease
AGEs, advanced glycation endproducts
AL, attenuation line
ALT, alanine aminotransferase
AR, anterior right
ATP III, adult treatment panel 3

B

BMI, body mass index

C

(-CH₂-)_n, methylene
CRP, C-reactive protein
CSI, chemical shift imaging
CT, computed tomography
CVD, cardiovascular disease

F

FLD, fatty liver disease (including AFLD and NAFLD)

G

GGT, gamma-glutamyl aminotransferase
GLUT-4, glucose transporter number 4

H

HC, hepatocyte
HCC, hepatocellular carcinoma
HDL, high density lipoprotein
HFFAs, hepatic free fatty acids
¹H MRS, magnetic resonance spectroscopy
H₂O, water
HOMA-_{IR}, insulin resistance by homeostatic model assessment
HSC, Hepatic Stellate Cell

I

IDF, international diabetes federation
IL-6, interleukin 6
IP, in-phase

K

KC, Kupffer Cell

L

LDL, low density lipoprotein

M

MetS, metabolic syndrome

MetS, metabolic syndrome

MR, magnetic resonance

MRI, magnetic resonance imaging

mRNA, messenger ribonucleic acid

N

NAFLD, non-alcoholic fatty liver disease (including NAS and NASH)

NAS, non-alcoholic steatosis

NASH, non-alcoholic steatohepatitis

NEFA, non-esterified fatty acids

NF- κ B, nuclear factor kappa-beta

O

OP, out-phase

P

PL, posterior left

PPAR, peroxisome proliferator-activated receptor

ppm, parts per million

PRESS, point resolved spectroscopy

R

ROI, region of interest

S

SAT, subcutaneous adipose tissue

T

TE, echo time

TGs, triglycerides

TNF α , tumour necrosis factor-alpha

TR, repetition time

V

VAT, visceral adipose tissue

VLDL, very low density lipoprotein

